NASDAQ
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Open
$41.64
Previous Close
$40.94
Day High
$41.64
Day Low
$39.50
52 Week High
$46.01
52 Week Low
$14.80
No price data available for this timeframe.